Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender: Results from the PROBE-HF study

Clinical Research in Cardiology

Volumn 105, Issue 5, 2016, Pages 421-431

  Ballo, Piercarlo ^a   Betti, Irene ^a   Barchielli, Alessandro ^b   Balzi, Daniela ^c   Castelli, Gabriele ^d   De Luca, Leonardo ^e   Gheorghiade, Mihai ^f   Zuppiroli, Alfredo ^c  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b Center for the Study and Prevention of Oncology   (Italy)

^c Local Health Authority   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e EUROPEAN HOSPITAL   (Italy)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetes; Hypertension; Natriuretic peptide; Primary care; Risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENDER; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; ASYMPTOMATIC DISEASE; BLOOD; CHI SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEX DIFFERENCE; TIME FACTOR;

AGE FACTORS; AGED; ASYMPTOMATIC DISEASES; BIOMARKERS; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84946780692     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0937-x     Document Type: Article

References (62)

1. Schneider HG, Lam L, Lokuge A et al (2009) B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med 150:365–371
2. Rosenberg J, Schou M, Gustafsson F, Badskjaer J, Hildebrandt P (2009) Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J 30:66–73
3. Frankenstein L, Remppis A, Nelles M et al (2008) Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J 29:2634–2640
4. Vazquez R, Bayes-Genis A, Cygankiewicz I, MUSIC Investigators et al (2009) The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 30:1088–1096
5. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663
6. Leistner DM, Klotsche J, Pieper L et al (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 102:259–268
7. Linssen GC, Bakker SJ, Voors AA et al (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31:120–127
8. Kara K, Mahabadi AA, Geisel MH et al (2014) B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events–the Heinz Nixdorf recall study. Clin Res Cardiol 103:125–132
9. Klaar U, Gabriel H, Bergler-Klein J et al (2011) Prognostic value of serial B-type natriuretic peptide measurement in asymptomatic organic mitral regurgitation. Eur J Heart Fail 13:163–169
10. Daniels LB, Clopton P, Jiang K, Greenberg B, Maisel AS (2010) Prognosis of stage A or B heart failure patients with elevated B-type natriuretic peptide levels. J Card Fail 16:93–98
11. Huelsmann M, Neuhold S, Strunk G et al (2008) NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 29:2259–2264
12. Pedersen F, Raymond I, Kistorp C, Sandgaard N, Jacobsen P, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide in arterial hypertension: a valuable prognostic marker of cardiovascular events. J Card Fail 11:S70–S75
13. Loke I, Squire IB, Davies JE, Ng LL (2003) Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 5:599–606
14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982
15. Betti I, Castelli G, Barchielli A et al (2009) The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure.The PROBE-HF study. J Card Fail 15:377–384
16. Yancy CW, Jessup M, Bozkurt B et al (2013) ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 128:e240–e327
17. Mancia G, Fagard R, Narkiewicz K et al (2013) ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J 34:2159–2219
18. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. World Health Org, Geneva
19. Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 16:233–270
20. Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 18:1440–1463
21. Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165–193
22. Vahanian A, Baumgartner H, Bax J et al (2007) The task force on the management of valvular heart disease of the European society of cardiology. Eur Heart J 28:230–268
23. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R (2004) Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 6:365–368
24. McKie PM, Cataliotti A, Lahr BD et al (2010) The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol 55:2140–2147
25. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616
26. Onodera M, Nakamura M, Tanaka F et al (2012) Plasma B-type natriuretic peptide is useful for cardiovascular risk assessment in community-based diabetes subjects: comparison with albuminuria. Int Heart J 53:176–181
27. Januzzi JL, van Kimmenade R, Lainchbury J et al (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27:330–337
28. Rodeheffer RJ, Jacobsen SJ, Gersh BJ et al (1993) The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 68:1143e50
29. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D (1993) Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88:107e15
30. Dini FL, Whalley G, Poppe K et al (2009) Plasma N-terminal protype-B natriuretic peptide and restrictive mitral flow to risk-stratify patients with stage B heart failure. Clin Cardiol 32:711–717
31. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA (2008) Biomarkers to predict recurrent cardiovascular disease: the heart and soul study. Am J Med 121:50–57
32. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA (2007) N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297:169–176
33. Fradley MG, Larson MG, Cheng S et al (2011) Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham heart study). Am J Cardiol 108:1341–1345
34. Gustafsson F, Steensgaard-Hansen F, Badskjær J, Poulsen AH, Corell P, Hildebrandt P (2005) Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 11:S15–S20
35. Hildebrandt P, Collinson PO, Doughty RN et al (2010) Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 31:1881–1889
36. Nielsen OW, Kirk V, Bay M, Boesgaard S, Nielsen H (2004) Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital heart failure study (CHHF). Eur J Heart Fail 6:275–279
37. Frankenstein L, Clark AL, Goode K et al (2009) The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age. Heart 95:825–829
38. Olsen MH, Hansen TW, Christensen MK et al (2008) Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens 26:26–34
39. Franke J, Lindmark A, Hochadel M et al (2015) Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the heart failure survival score. Clin Res Cardiol 104:334–341
40. Kara K, Lehmann N, Neumann T et al (2015) NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf recall study. Int J Cardiol 183:155–161
41. Christ M, Laule-Kilian K, Hochholzer W et al (2006) Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 48:1808–1812
42. Nakamura M, Tanaka F, Onoda T et al (2010) Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. Int J Cardiol 143:124–129
43. Schroten NF, Damman K, Valente MA et al (2015) Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clin Res Cardiol. doi:10.1007/s00392-015-0881-9
44. Ogah OS, Davison BA, Sliwa K et al (2015) Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: results of the THESUS-HF study. Clin Res Cardiol 104:481–490
45. Meyer S, Brouwers FP, Voors AA et al (2015) Sex differences in new-onset heart failure. Clin Res Cardiol 104:342–350
46. Ballo P, Betti I, Barchielli A et al (2013) Body mass index, gender, and clinical outcome among hypertensive and diabetic patients with stage A/B heart failure. Obesity 21:E500–E507
47. Schocken DD, Benjamin EJ, Fonarow GC et al (2008) Prevention of heart failure: a scientific statement from the American heart association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group. Circulation 117:2544e65
48. Daugherty SL, Masoudi FA, Ellis JL et al (2011) Age-dependent gender differences in hypertension management. J Hypertens 29:1005–1011
49. Homko CJ, Zamora L, Santamore WP, Kashem A, McConnell T, Bove AA (2010) Gender differences in cardiovascular risk factors and risk perception among individuals with diabetes. Diabetes Educ 36:483–488
50. Scirica BM, Morrow DA, Bode C et al (2010) Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 31:1993–2005
51. Staub D, Nusbaumer C, Zellweger MJ et al (2006) Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J 151:1223–1230
52. Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P (2009) N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 26:872–879
53. Poulsen MK, Henriksen JE, Vach W et al (2010) Identification of asymptomatic type 2 diabetes mellitus patients with a low, intermediate and high risk of ischaemic heart disease: is there an algorithm? Diabetologia 53:659–667
54. Singh HS, Bibbins-Domingo K, Ali S, Wu AH, Schiller NB, Whooley MA (2009) N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. Clin Cardiol 32:447–453
55. Wiersma JJ, van der Zee PM, van Straalen JP et al (2009) NT-pro-BNP is associated with inducible myocardial ischemia in mildly symptomatic type 2 diabetic patients. Int J Cardiol 145:295–296
56. Kováts T, Wettstein A, Nagy E, Tomcsányi J (2008) Bradycardia can induce increased serum natriuretic peptide-level. Int J Cardiol 123:e43–e44
57. Baggish AL, van Kimmenade RR, Januzzi JL Jr (2008) The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol 101:43–48
58. Kováts T, Tomcsányi J (2009) Bradycardia and B-type natriuretic peptide. Int J Cardiol 145:238–239
59. Sinning C, Kieback A, Wild PS et al (2014) Association of multiple biomarkers and classical risk factors with early carotid atherosclerosis: results from the Gutenberg Health Study. Clin Res Cardiol 103:477–485
60. Takeishi Y (2014) Biomarkers in heart failure. Int Heart J 55:474–481
61. Friões F, Lourenço P, Laszczynska O et al (2015) Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol 104:491–499
62. Bayes-Genis A, Ordonez-Llanos J (2015) Multiple biomarker strategies for risk stratification in heart failure. Clin Chim Acta 443:120–125